🇺🇸 FDA

Company profile · Sponsor

Pharm

Pharm Research Associates (UK) Limited

E917DBA · EMA pharma GB
Pipeline
24
Drugs
0
Patents
0

Quick answer

Pharm (E917DBA) is a pharma company. headquartered in GB. listed on EMA. NovaPharmaNews links 24 pipeline programs, 0 drugs, and 0 patents to this profile..

Company facts

Ticker E917DBA
Exchange EMA
Company type pharma
Headquarters GB

Pipeline (24)

Search pipeline →

  1. Acnatac 10mg/g + 0,25mg/g Gel, Clindamycin Tretinoin Gel, Vehicle to Clindamycin Tretinoin Gel

    Pharm

    Papulopustular acne

    phase 3 small molecule active

    1 trial

  2. Clinical study to compare the therapeutic effects of two ointments with active substances betamethasone dipropionate and salicylic acid and of one ointment without active substances for patients with chronic stable plaque poriasis

    Pharm

    Chronic stable plaque psoriasis

    phase 3 other active

    1 trial

  3. Double-blind, randomised clinical study comparing efficacy and safety of Mecloderm® Cream (Test) vs. Lotricomb® Cream (Reference) vs. Vehicle in patients with moderate to severely inflamed candidiasis of the skin

    Pharm

    moderate to severely inflamed candidiasis of the skin

    phase 3 other active

    1 trial

  4. InfectoScab® 5 % Crème, Permethrin, DRIPONIN 3 mg Tabletten

    Pharm

    Scabies

    phase 3 small molecule active

    1 trial

  5. LANREOTIDE, LANREOTIDE, Debio 4126, Debio 4126, Ready-to-use suspension resembling 30, 60, or 90 mg Debio 4126 doses, Debio 4126, OCTREOTIDE, OCTREOTIDE, LANREOTIDE, OCTREOTIDE

    Pharm

    Acromegaly

    phase 3 small molecule active

    1 trial

  6. Methylprednisolone Aceponate Cream, Advantan 0.1% cream, Vehicle to Methylprednisolone Aceponate Cream

    Pharm

    Mild to moderate atopic dermatitis

    phase 3 small molecule active

    1 trial

  7. Permethrin, InfectoScab® 5 % Crème

    Pharm

    Scabies

    phase 3 small molecule active

    1 trial

  8. SanaCutan® Basiscreme

    Pharm

    Children with a high risk of developing atopic dermatitis

    phase 3 small molecule active

    1 trial

  9. Solcera, Preserved water

    Pharm

    Actinic keratosis

    phase 3 small molecule active

    1 trial

  10. Vehicle to Mecloderm Ointment, LOTRICOMB® Salbe, 0,64 mg/g + 10 mg/g, Salbe, Mecloderm Ointment

    Pharm

    moderate to severely inflamed candidiasis of the skin

    phase 3 small molecule active

    1 trial

  11. Vehicle to Test Product, Ivermectin Cream, Soolantra 10 mg/g Creme

    Pharm

    Papulopustular Rosacea

    phase 3 small molecule active

    1 trial

  12. [68Ga]Ga-PentixaFor, FLUDEOXYGLUCOSE (18F)

    Pharm

    Marginal Zone Lymphoma

    phase 3 small molecule active

    1 trial

  13. A Phase 2, Multiple Ascending Dose, Open-label, Proof-of-concept Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Activity of HM15136 Treatment for 8 Weeks in Subjects Aged ≥2 Years With Congenital Hyperinsulinism (CHI) (ACHIEVE)

    Pharm

    Congenital Hyperinsulinism (CHI)

    phase 2 other active

    1 trial

  14. Balstilimab, CR6086, CR6086

    Pharm

    Pretreated mismatch-repair-proficient and microsatellite stable metastatic colorectal cancer, and other metastatic GI cancers

    phase 2 small molecule active

    1 trial

  15. Debio 4228, Debio 4228

    Pharm

    advanced prostate cancer

    phase 2 small molecule active

    1 trial

  16. Radotinib HCl, Placebo for Radotinib HCl

    Pharm

    Treatment of Parkinson’s disease (PD)

    phase 2 small molecule active

    1 trial

  17. Solution for injection in pre-filled syringe

    Pharm

    Short Bowel Syndrome-associated Intestinal Failure (SBS-IF)

    phase 2 small molecule active

    1 trial

  18. WSD0922-FU, WSD0922-FU

    Pharm

    Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  19. [90Y]Y-PentixaTher, LysaKare 25 g/25 g solution for infusion, [68Ga]Ga-PentixaFor

    Pharm

    Central nervous system (CNS) lymphoma; recurrent or refractory primary or isolated secondary

    phase 2 small molecule active

    1 trial

  20. A Study to Evaluate Safety and Preliminary Anti-tumor Activity of Debio 0123 as Monotherapy in Adult Participants With Advanced Solid Tumors

    Pharm

    Arm A: Diagnosed with uterine serous carcinoma (USC) Arm B: Diagnosed with recurrent or progressive, high-grade epithelial ovarian cancer (EOC) with cyclin E1-driven selection Arm C: Diagnosed with solid tumor with biomarker-driven selection

    phase 1 other active

    1 trial

  21. A first-in-human trial to evaluate safety, tolerability, and pharmacokinetics of single and multiple oral doses of Debio 1453P in healthy adults

    Pharm

    Sexual Transmitted Infection (STI)

    phase 1 other active

    1 trial

  22. A phase 1 study of oral Debio 0123 in combination with carboplatin in patients with advanced solid tumors

    Pharm

    Patients with tumors

    phase 1 other active

    1 trial

  23. Bioequivalence of two transdermal therapeutic systems delivering 100 mcg/h fentanyl

    Pharm

    Bioequivalence trial in healthy volunteers

    phase 1 other active

    1 trial

  24. Bioequivalence of two transdermal therapeutic systems delivering 100 mcg/h fentanyl

    Pharm

    Bioequivalence trial in healthy volunteers

    phase 1 other active

    1 trial

Frequently asked questions

What is Pharm?

Pharm (E917DBA) is a pharma company. headquartered in GB. listed on EMA. NovaPharmaNews links 24 pipeline programs, 0 drugs, and 0 patents to this profile..

What pipeline programs does Pharm sponsor?

We track 24 ClinicalTrials.gov-linked programs for Pharm, including Acnatac 10mg/g + 0,25mg/g Gel, Clindamycin Tretinoin Gel, Vehicle to Clindamycin Tretinoin Gel and 23 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Pharm company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.